Efruxifermin is in clinical trials for the treatment of NASH
Lower cost from a compounding pharmacy source is not inherently suspicious but it does warrant independent verification of the pharmacys FDA registration status
Saxenda Saxenda (liraglutide) is an FDA-approved, injectable prescription medicine that may help some adults with obesity lose weight and maintain weight loss (together with reduced-calorie diet and physical activity)
Six prescription compounds across four mechanism classes , including formats SHED does and doesnt carry: Microdose GLP-1 Protocol at $129/mo flat (capsule, troche, lozenge, sublingual delivery variants), Semaglutide Oral from $289/mo, Semaglutide Injection at $189/mo, Tirzepatide Injection at $289/mo, Tirzepatide Oral at $349/mo, and GLP-Squared dual-compound therapy at $289/mo
This timeline is based on semaglutide's half-life (approximately one week) and a precautionary principle, not definitive evidence of danger
Gromada J, Hughes TE